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VaOBJECTIVES This study sought to evaluate a ventilation maneuver to facilitate percutaneous edge-to-edge mitral
valve repair (PMVR) and its effects on heart geometry.
BACKGROUND In patients with challenging anatomy, the application of PMVR is limited, potentially resulting in
insufﬁcient reduction of mitral regurgitation (MR) or clip detachment. Under general anesthesia, however, ventilation
maneuvers can be used to facilitate PMVR.
METHODS A total of 50 consecutive patients undergoing PMVR were included. During mechanical ventilation, different
levels of positive end-expiratory pressure (PEEP) were applied, and parameters of heart geometry were assessed using
transesophageal echocardiography.
RESULTS We found that increased PEEP results in elevated central venous pressure. Speciﬁcally, central venous
pressure increased from 14.0  6.5 mm Hg (PEEP 3 mm Hg) to 19.3  5.9 mm Hg (PEEP 20 mm Hg; p < 0.001). As a
consequence, the reduced pre-load resulted in reduction of the left ventricular end-systolic diameter from 43.8 10.7 mm
(PEEP 3 mm Hg) to 39.9  11.0 mm (PEEP 20 mm Hg; p < 0.001), mitral valve annulus anterior-posterior diameter from
32.4  4.3 mm (PEEP 3 mm Hg) to 30.5  4.4 mm (PEEP 20 mm Hg; p < 0.001), and the medio-lateral diameter from
35.4  4.2 mm to 34.1  3.9 mm (p ¼ 0.002). In parallel, we observed a signiﬁcant increase in leaﬂet coaptation length
from 3.0  0.8 mm (PEEP 3 mm Hg) to 5.4  1.1 mm (PEEP 20 mm Hg; p < 0.001). The increase in coaptation length was
more pronounced in MR with functional or mixed genesis. Importantly, a coaptation length>4.9 mm at PEEP of 10 mmHg
resulted in a signiﬁcant reduction of PMVR procedure time (152  49 min to 116  26 min; p ¼ 0.05).
CONCLUSIONS In this study, we describe a novel ventilation maneuver improving mitral valve coaptation length during
the PMVR procedure, which facilitates clip positioning. Our observations could help to improve PMVR therapy and
could make nonsurgical candidates accessible to PMVR therapy, particularly in challenging cases with functional MR.
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ABBR EV I A T I ON S
AND ACRONYMS
CVP = central venous pressure
LVEF = left ventricular ejection
fraction
LVESD = left ventricular end-
systolic diameter
MR = mitral regurgitation
PEEP = positive end-expiratory
pressure
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152P ercutaneous mitral valve repair(PMVR) using the MitraClip system(Abbott Vascular, Santa Clara, Califor-
nia) is an innovative method for the treat-
ment of mitral regurgitation (MR) in
patients who are not accessible by conven-
tional operation. Since the ﬁrst randomized
controlled trial, which included preferen-
tially patients with MR caused by degen-
eration of the valve, the application of
PMVR has tremendously increased over
the last decade (1). A subgroup analysis
of the EVEREST II (Endovascular Valve
Edge-to-Edge Repair) trial suggested thatbesides older patients, those with functional MR
particularly proﬁt from PMVR (2). A major advan-
tage of the interventional approach over conven-
tional operation is the avoidance of open-heart
surgery with no major injuries and no need for
extracorporeal circulation (3,4). Recent trials sug-
gested a beneﬁt of PMVR in high-risk patients
(5,6), patients with severe left ventricular dysfunc-
tion (7), or nonresponders to cardiac resynchroniza-
tion therapy (8).
Indication expansion for a procedure is usually
paralleled by the appearance of novel pitfalls and
obstacles, which become apparent when more
challenging cases are treated. A major disadvantage
of PMVR in comparison to conventional operation is
that mitral valve reconstruction cannot be carried
out by a direct approach providing complete
direct vision of mitral valve pathology. Thus, clip
delivery using an interventional PMVR device
can be challenging and sometimes frustrating (9).
Recent technical progress such as the application of
3-dimensional transesophageal echocardiography
(TEE) has revolutionized the PMVR procedure,
increased periprocedural comfort, and immensely
improved success in MR reduction (10). Neverthe-
less, challenging anatomies still limit application of
the procedure. For instance, mitral valve regurgita-
tion due to degenerative disease with severe calci-
ﬁcations, reduced coaptation length and depth,
or reduced leaﬂet mobility length may preclude
PMVR, and may cause insufﬁcient reduction ofwas supported by grants from the German research foundation
he “Juniorprofessorenprogramm of the county Baden-Wuerttemb
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received June 15, 2015; revised manuscript received August 31, 2MR, embolization of the device, or procedural fail-
ure (11).
Although recent reports (12) and our own experi-
ence indicate that interventional therapy of MR is
feasible under deep sedation in some patients, the
procedure is generally carried out under general
anesthesia with its potential disadvantages, such
as hypotensive episodes, aspiration, or post-
interventional delirium in these frail patients.
Mechanical ventilation is furthermore paralleled
by hemodynamic changes. For instance, acute appli-
cation of positive end-expiratory pressure (PEEP) re-
sults in reduction of transmural cardiac ﬁlling
pressures, cardiac index, and stroke index (13). In
another clinical setting, it has been reported that
continuous positive airway pressure ventilation
over a period of 3 months leads to reduction of
mitral regurgitant fraction and an increase in left
ventricular ejection fraction in patients with chronic
heart failure (14). Moreover, an immediate reduc-
tion of MR and a signiﬁcant increase in left ven-
tricular ejection fraction (LVEF) after 30 min of
continuous positive airway pressure ventilation
or bilevel ventilation was observed (15). As me-
chanical ventilation under general anesthesia at
present is the gold standard for PMVR, it is
important not only to consider its previously
mentioned drawbacks, but also to take advantage of
hemodynamic alterations induced by mechanical
ventilation.
Here, we report a novel concept of using a high
PEEP to increase coaptation length of the anterior and
posterior leaﬂet of the mitral valve to facilitate the
PMVR procedure.
METHODS
STUDY POPULATION. Between May 2014 and
August 2015, 81 patients with grade 3 or 4 MR un-
derwent PMVR at the University Hospital, Depart-
ment for Cardiology and Cardiovascular Medicine,
University of Tuebingen. We measured echocardio-
graphic changes at different PEEP levels in 50 pa-
tients. A total of 26 patients were not included, as
they underwent the procedure in deep sedation(KFO 274), the Volkswagen foundation (Lichtenberg
erg,” and the German Heart foundation. Dr. Hansen
om Medtronic and St. Jude Medical. Dr. Langer was
itral valve repair procedure. All other authors have
er to disclose.
015, accepted September 10, 2015.
TABLE 1 Baseline Patient Characteristics (n ¼ 50)
Age, yrs 74.8 (38–91)
Male 30 (60.0)
Coronary heart disease 39 (78.0)





NYHA functional class 3–4 44 (88.0)
Renal insufﬁciency 34 (68.0)










Aldosterone antagonist 31 (62.0)
ACE inhibitors/sartans 47 (94.0)
Diuretic agents 46 (92.0)
Digitalis 4 (8.0)
Calcium antagonists 7 (14.3)
Anticoagulation 37 (74.0)
Values are mean (range), n (%), mean  SD.
ACE ¼ angiotensin-converting enzyme; LV ¼ left ventricular; LVEDD ¼ left
ventricular end-diastolic diameter; NYHA ¼ New York Heart Association.
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153without endotracheal intubation. In 5 patients, no
measurements were obtained due to the critical
state of the patient. The study was approved by the
local ethics committee (260/2015R). In patients with
high-grade MR and a high surgical risk, the indica-
tion for treatment of MR was assessed according to
the current guidelines by an interdisciplinary team
of interventional cardiologists and cardiac surgeons.
The stratiﬁcation of surgical risk was based on
either the EuroSCORE (European System for Cardiac
Operative Risk Evaluation) (16) or on the presence
of speciﬁc surgical risk factors not covered in the
EuroSCORE. Valve anatomy was also assessed by
the interdisciplinary team as to the suitability for
MitraClip treatment. Exclusion criteria for mitral
clipping were a transmitral gradient >5 mm Hg
(as evaluated by Doppler echocardiography), active
endocarditis, severely degenerated valve mor-
phology such as extensively prolapsed or ﬂail leaf-
lets (prolapse width >25 mm, ﬂail gap >20 mm),
heavy calciﬁcations, or a retracted posterior leaﬂet
shorter than 8 mm. All patients underwent trans-
thoracic echocardiography (TTE), TEE, and clinical
assessment before the intervention to assess MR
severity, mitral valve morphology, and New York
Heart Association functional class. Heart failure
patients had to be on optimal medical treatment
according to current guidelines for at least 3 months
prior to MitraClip treatment.
ECHOCARDIOGRAPHIC ASSESSMENT. TTE and TEE
were performed in all patients within 30 days prior
to the procedure using a Philips CX 50 and iE 33
machine (Philips HealthCare, Hamburg, Germany).
The severity of MR at baseline and the etiology of
the mechanism of regurgitation were determined
according to the current European Association of
Echocardiography guidelines (17). Post-intervention,
the severity of MR was assessed according to the
technique described by Foster et al. (18). Post-
interventional echocardiographic measurements
were carried out immediately after clip implanta-
tion. All echocardiographic loops were recorded. A
total of 6 additional investigators blinded to the
PEEP maneuver repeated measurements using the
Centricity Enterprise Web 3.0 software (GE Medical
Systems, Barrington, Illinois). The mean of mea-
surements was calculated and taken as a ﬁnal value.
PMVR PROCEDURE. After induction of general anes-
thesia, the TEE probe was introduced into the
esophagus. The intercommissural and septolateral
views of the mitral valve were obtained in a mid-
esophageal view at 50 to 70 and 140 to 160,
respectively. Coaptation length of the mitral valvewas measured in the septolateral view at different
PEEP levels (3, 10, and 20 mm Hg). All echocardio-
graphic parameters after PEEP modiﬁcations were
assessed when the central venous pressure (CVP) had
reached a steady state value. CVP was obtained via a
jugular central venous line. PMVR procedure time
was deﬁned as the start time of the ﬁrst venous
puncture to the time of closure of the puncture
wound. Using ﬂuoroscopic and transesophageal
2- and 3-dimensional echocardiographic guidance,
the MitraClip device was advanced via the trans-
septal route across the mitral annulus into the left
ventricle. With the 2 arms of the clip extended,
the device was retracted to capture and subse-
quently closed to coapt the mitral leaﬂets, thereby
emulating the surgical double-oriﬁce technique
introduced by Alﬁeri et al. (19). After clip deploy-
ment and right heart catheterization using a Swan-
Ganz catheter, ﬁnal TEE and TTE measurements
were performed.
STATISTICAL ANALYSIS. Statistical analysis was
performed with SPSS (version 22, IBM Deutschland
GmbH, Ehningen, Germany). Categorical variables
FIGURE 1 Severity of MR at Baseline and After Clip
Implantation in Subgroups of Functional, Degenerative,
and Mixed Genesis of MR
A total of 50 patients with grade 3 or 4 mitral regurgitation (MR)
underwent percutaneous mitral valve repair (PMVR). MR before
PMVR (pre) and after PMVR (post) is depicted. deg ¼ degener-
ative MR; funct ¼ functional MR.
FIGURE 2 Effects of Increased PEEP on CVP and Left Ventricular Heart Geometry
(A)Duringpercutaneousmitral valve repair, thecentral venouspressure (CVP)wasdetermined
at positive end-expiratory pressure (PEEP) levels of 3 and20mmHg (n¼ 50; p<0.001). (B to
D)TEEwas used to assess left ventricular end-systolic diameter (LVESD) andmitral valve (MV)
annulus diameters. (B) At PEEP levels of 3, 10, and 20 mm Hg, we observed a signiﬁcant
reduction of LVESD diameter with elevated PEEP (n ¼ 50; p < 0.001 vs. PEEP 3 mm Hg).
(C) The anteroposterior (ap) diameter showed a signiﬁcant reduction at higher PEEP levels
(n ¼ 50; p < 0.001 vs. PEEP 3 mm Hg). (D) Similarly, a reduction of the mediolateral (ml)
annulus diameter at higher PEEP levels was observed (n¼ 50; p¼ 0.002 vs. PEEP 3mmHg).
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154are presented as absolute numbers or percent-
ages and continuous variables as mean  SD.
Kolmogorov-Smirnov and Shapiro-Wilk tests were
performed to examine for normal distribution of
variables. All variables showed normal distribution,
and parametric tests were used for statistical com-
parison. For patient analysis, the paired Student
t test was used to compare means. Intergroup
comparisons were performed by analysis of vari-
ance. The 2-tailed p values were calculated, and a
value of p < 0.05 was considered statistically sig-
niﬁcant. Echocardiographic views were assessed by
7 independent investigators, 6 of whom were blin-
ded to the results. The intraclass correlation coef-
ﬁcient for absolute agreement was used to assess
reproducibility of echocardiographic measurements,
with good agreement deﬁned as >0.80. For the
assessment of intraobserver reliability, 20 randomly
chosen patients were analyzed by 1 investigator
twice. Absolute agreement among the observations
was calculated using intraclass correlation coefﬁ-
cient analysis.
RESULTS
PMVR is commonly carried out under general anes-
thesia. Mechanical ventilation causes hemodynamic
changes, offering possibilities to modify heart geom-
etry. Here, we evaluated the effects of different PEEP
levels applied during PMVR on different hemody-
namic and anatomical parameters inﬂuencing the
interventional procedure.
In 50 patients undergoing PMVR in general
anesthesia, we evaluated the inﬂuence of different
PEEP levels on central venous pressure and on
heart geometry. Table 1 shows the baseline charac-
teristics for all patients. The majority of patients
had New York Heart Association functional class III
to IV (88.0%), and there was a high percentage
of patients with severely reduced (<35% ejection
fraction) left ventricular function (i.e., 50.0%).
Functional MR was present in 46.0% of the patients
and degenerative MR in 30.0% of the patients. A
total of 78.0% of the patients had previously diag-
nosed coronary artery disease, 70.0% atrial ﬁbrilla-
tion, and 68.0% renal insufﬁciency. Before and after
PMVR, MR and reduction of MR by the intervention
was assessed using TEE. Figure 1 depicts severity
and genesis of MR. All patients had successful
reduction of MR after PMVR. During PMVR, we
monitored changes in CVP depending on different
PEEP values (3 and 20 mm Hg). At a PEEP level of
3 mm Hg, mean CVP values were 14.0.0  6.5 mm Hg,
whereas PEEP levels of 20 mm Hg resulted in CVP of
TABLE 2 Intraclass Correlations for Interobserver and Intraobserver Agreement of
Echocardiographic Measurements
Interobserver Agreement p Value Intraobserver Agreement p Value
Coaptation
3 mm Hg 0.88 <0.001 0.91 <0.001
10 mm Hg 0.92 <0.001 0.94 <0.001
20 mm Hg 0.90 <0.001 0.98 <0.001
Annulus a.-p.
3 mm Hg 0.95 <0.001 0.80 <0.001
10 mm Hg 0.96 <0.001 0.86 <0.001
20 mm Hg 0.94 <0.001 0.91 <0.001
Annulus m.-l.
3 mm Hg 0.96 <0.001 0.95 <0.001
10 mm Hg 0.96 <0.001 0.86 <0.001
20 mm Hg 0.94 <0.001 0.95 <0.001
LVESD
3 mm Hg 0.98 <0.001 1.00 <0.001
10 mm Hg 0.98 <0.001 0.99 <0.001
20 mm Hg 0.95 <0.001 0.98 <0.001
Interobserver and intraobserver agreement for echocardiographic measurements at different positive
end-expiratory pressure levels.
a.-p. ¼ anteroposterior diameter; LVESD ¼ left ventricular end-systolic diameter; m.-l. ¼ medio-lateral
diameter.
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15519.3  5.9 mm Hg (p < 0.001), indicating an increase of
intrathoracic pressure (Figure 2A). End-systolic medio-
lateral (intercommissural) and anterior-posterior di-
ameters of the mitral valve annulus as well as the left
ventricular end-systolic diameter (LVESD) in the
septo-lateral view were measured at PEEP levels of 3,
10, and 20 mm Hg. Interestingly, we observed
geometrical alterations of the LVESD (Figure 2B) and of
the mitral valve annulus diameter (Figures 2C and 2D),
respectively, with rising PEEP. The LVESD decreased
from 43.8 10.7 mm (PEEP 3mmHg) to 39.9 11.0 mm
(PEEP 20 mm Hg; p < 0.001) (Figure 2B). Accordingly,
both the medio-lateral diameter (35.4  4.2 mm at
PEEP 3 mm Hg, 34.1  3.9 mm at PEEP 20 mm Hg;
p ¼ 0.002) and the anterior-posterior diameter
(32.4  4.3 at PEEP 3 mm Hg, 30.5  4.4 at PEEP
20 mm Hg; p < 0.001) of the mitral valve annulus
showed a signiﬁcant decrease (Figures 2C and 2D).
Table 2 shows intraobserver and interobserver vari-
ability of echocardiographic measurements. In the
following, coaptation length of themitral valve leaﬂets
was measured at the respective PEEP settings in end-
systole. As illustrated in Figure 3A, mechanical venti-
lation offers the possibility to modify hemodynamics
during the PMVR procedure. Applying an increased
PEEP, the altered heart geometry results in a decrease
of the mitral valve annulus size and subsequently an
increase of mitral valve leaﬂet coaptation length.
Figure 3B exempliﬁes how the leaﬂet coaptation length
was measured and provides sample images of coapta-
tion length increase upon PEEP elevation. In parallel to
a reduction of LVESD and mitral valve annulus diam-
eter, we observed a signiﬁcant ampliﬁcation of mitral
valve leaﬂet coaptation length from 3.00.8mm to 4.2
 0.9 mm to 5.4 1.1 mm at PEEP levels of 3, 10, and 20
mm Hg, respectively (p < 0.001) (Figure 3C). This in-
crease in coaptation length provides more leaﬂet ma-
terial for a potentially facilitated grip. To account for a
possible difference regarding augmentation of leaﬂet
coaptation in different mitral valve pathologies, we
analyzed the subsets of MR genesis (i.e., functional MR
vs. degenerative vs. mixed genesis) for differences in
coaptation length-increase. In particular, we found
that coaptation length increased in all 3 subgroups
with elevated PEEP (Figure 4). Interestingly, in func-
tional MR and in MR with a mixed genesis, the coap-
tation length increase was more pronounced than in
degenerative MR (p ¼ 0.02) (Figure 4). Importantly,
increased coaptation length had an effect on procedure
time. For instance, time to successful clip delivery
deﬁned by a reduction of MR by at least 2 was
decreased signiﬁcantly by z24% in patients with a
mitral valve leaﬂet coaptation length $4.9 mm
measured at an intermediate PEEP level of 10 mm Hg(Figure 5). Speciﬁcally, the procedure time in patients
with a coaptation length <4.9 mm was 152  49 min
compared with 116  26 min in patients with an
increased leaﬂet coaptation length (p ¼ 0.05)
(Figure 5). There were no signiﬁcant differences in
atrial diameter between the 2 groups (data not
shown) or any transseptal problems that might
explain the differences in procedure times. Further-
more, the baseline characteristics were not signiﬁ-
cantly different between the 2 groups (data not
shown). These observations indicate that an increase
in mitral valve coaptation length could facilitate the
PMVR procedure.
DISCUSSION
In this study, we describe application of PEEP as a
novel maneuver improving mitral valve coaptation
length during the PMVR procedure, which facilitates
clip positioning. This conclusion is supported by the
following data: 1) mitral valve coaptation length
shows a robust ampliﬁcation with increased PEEP
levels; 2) modiﬁcations in heart geometry (such as
reduction in mitral valve annulus diameter) can
explain this observed effect; and 3) increased coap-
tation length resulted in a signiﬁcant reduction of
PMVR procedure time.
PMVR using the MitraClip system is an innovative
method to treat MR in patients who are at high risk for
surgical treatment (20). Positioning of the clip remains
the most signiﬁcant challenge in PMVR. Different
FIGURE 3 Effects of Increased PEEP on MV Leaﬂet Coaptation
(A) Applying an increased PEEP, reduced venous return results in altered heart geometry (1). We measured a reduced left ventricular (LV)
diameter and decreased MV annulus diameter (2), paralleled by an ampliﬁcation of MV coaptation length (3). (B) Sample TEE recordings
(septo-lateral view). *Posterior MV leaﬂet; **anterior MV leaﬂet. The red line indicates the coaptation length measured at different PEEP
levels. (C) A signiﬁcant ampliﬁcation of MV leaﬂet coaptation length was measured by transesophageal echocardiography (TEE) at PEEP levels
of 3, 10, and 20 mm Hg (n ¼ 50; p < 0.001 vs. respective lower PEEP levels). Abbreviations as in Figure 2.
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156approaches have been suggested to improve the
PMVR procedure such as the induction of asystole/
bradycardia via an adenosine bolus injection or rapid
pacing (21). We recently described a case in which clip
positioning was facilitated after inducing temporary
asystole, with resulting cardiac arrest due to a pause>20 s preceding the ventricular escape rhythm in a
pacemaker-dependent patient (22).
Interestingly, it is known that continuous positive
airway pressure ventilation can reduce MR and
enhance LVEF in acute (15,23,24) or chronic heart
failure (14). However, acute application of PEEP is
FIGURE 4 Increase in MV Leaﬂet Coaptation Length at
Different PEEP Levels in Mitral Regurgitation of
Functional, Degenerative, or Mixed Genesis
The coaptation length of the anterior and posterior mitral valve
leaﬂet was measured by TEE at different PEEP levels after a
steady state CVP level had been reached as described in
Figure 3. The increase of coaptation length between PEEP
levels of 3 and 20 mm Hg in functional, degenerative, and
mixed genesis of mitral regurgitation is depicted. *p ¼ 0.02
versus functional mitral regurgitation. Abbreviations as in
Figures 2 and 3.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 2 , 2 0 1 6 Patzelt et al.
J A N U A R Y 2 5 , 2 0 1 6 : 1 5 1 – 9 PMVR and PEEP
157known to reduce cardiac index and stroke index (13).
Although it is reasonable to assume that these
hemodynamic changes have their correlation in an
altered cardiac chamber size and geometry, to our
knowledge no systematic imaging studies exist eval-
uating the effect of different PEEP levels on cardiac
geometry. On the basis of the consideration thatFIGURE 5 Increased MV Leaﬂet Coaptation Length Is
Associated With Reduced PMVR Procedure Time
The patient collective was divided in 2 groups according to
coaptation length at an intermediate PEEP level of 10 mm Hg.
In patients with an MV coaptation length of $4.9 mm, the
PMVR procedure time was signiﬁcantly reduced compared with
patients with a coaptation length <4.9 mm (n ¼ 42 for coap-
tation length <4.9 mm; *p ¼ 0.05). Abbreviations as in
Figures 1 and 2.reduced cardiac output is paralleled by a decrease of
cardiac chamber size and, as a consequence, by a
reduced size of the mitral annulus, we hypothesized
an ampliﬁcation of mitral coaptation length given
that leaﬂet length remains unchanged. Indeed, we
observed a signiﬁcant PEEP-dependent relationship
between coaptation length and the degree of PEEP
applied (PEEP 3 mm Hg: 3.0  0.8 mm to PEEP 20
mm Hg: 5.4  1.1 mm; p < 0.001).
STUDY LIMITATIONS. Certainly, we have to acknowl-
edge a limited sample size. For example, a subgroup
analysis of MR genesis (functional: n ¼ 23, degener-
ative: n ¼ 15, mixed: n ¼ 12) will need further
conﬁrmation with larger groups. Given the novelty of
the PMVR technique and its complexity, however, the
sample size seems reasonable, particularly as the ef-
fect on increase in leaﬂet adaptation was very robust
and “dose-dependent.” We cannot entirely rule out
the possibility that reduced afterload upon PEEP
increase mediates the observed changes in heart
geometry, although arterial blood pressure was kept
at a steady state by adjusting catecholamine doses.
Furthermore, other parameters such as ﬂuctuations
in catheter position, blood viscosity, or body tem-
perature may have altered the results, although
parameters were kept as constant as possible for
example by using an active self-warming blanket. As
we selected our patients according to the EVEREST
criteria, we had only 2 patients with a baseline
coaptation length <2 mm. Future trials will be needed
to assess effects of the PEEP maneuver in patients
with lesser leaﬂet coaptation.
POTENTIAL RISKS OF THE PEEP MANEUVER. The
grasping maneuver takes only few seconds, but
usually <1 min. Accordingly, elevated PEEP levels
were applied for only a short time. Nevertheless, po-
tential risks have to be taken into consideration. If
increased PEEP levels are kept over a longer period of
time, adverse effects on hemodynamics, particularly
in patients with severely reduced LVEF or who are
hemodynamically unstable, can lead to drops in arte-
rial blood pressure (13). In our patients, arterial blood
pressure was monitored invasively, and the PEEP
maneuver was stopped in case of hemodynamic
instability; thus, we observed no relevant adverse ef-
fects. Furthermore, high PEEP levels have been asso-
ciated with occurrence of a pneumothorax (25).
Accordingly, an extensive PEEP maneuver should not
be applied in patients with severe lung emphysema.
CLINICAL IMPLICATIONS. We measured the inﬂu-
ence of different PEEP levels on various parameters.
We found a signiﬁcant correlation between PEEP
PERSPECTIVES
WHAT IS KNOWN? Interventional therapy of MR is
beneﬁcial in patients not accessible by conventional
surgery, however, positioning of the MitraClip can be
challenging in certain valve anatomies precluding
PMVR.
WHAT IS NEW? Using ventilation maneuvers dur-
ing general anesthesia, this study describes a very
robust increase in mitral valve leaﬂet coaptation
length with increasing PEEP levels during PMVR
paralleled by corresponding changes in heart
geometry, for instance, reduced LVESD and
reduced mitral valve annulus diameter. Above a
threshold of a coaptation length >4.9 mm at PEEP
of 10 mm Hg, PMVR procedure time was signiﬁ-
cantly decreased.
WHAT IS NEXT? Further studies are needed to
evaluate procedure success applying the pro-
posed ventilation maneuver in a prospective
fashion and enrolling patients with a mitral valve
leaﬂet coaptation length of #2 mm—an exclusion
criterion according to the early EVEREST
speciﬁcations.
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This ﬁnding points out a beneﬁcial maneuver to
facilitate the grasping of the leaﬂets in patients with
difﬁcult valve anatomies.
It is tempting to speculate that applying ventila-
tion with an increased PEEP for the short time of
grasping the leaﬂets could improve success rates for
PMVR. This hypothesis is supported by our ﬁnding
that the PMVR procedure time was substantially
shorter in patients when the mitral valve coaptation
length reached a certain value. Given the fact that
PMVR is also possible in deep sedation (12), our
ﬁndings may inﬂuence the choice of anesthesia,
particularly in challenging cases of mitral valve
morphology. It has to be considered, however, that
after a successful grip, leaﬂet insertion has to be
re-evaluated after reversing to normal PEEP levels,
because our measurements indicate that changed
hemodynamics alter heart and particularly valve
morphology. Moreover, it has to be kept in mind that
high PEEP levels are not tolerated for a long time, and
it is helpful to test effects of temporarily elevated
PEEP levels on hemodynamics, for instance, arterial
blood pressure, in these fragile patients at the
beginning of the procedure.
CONCLUSIONS
In this study, we describe the application of elevated
PEEP as a novel maneuver improving mitral valve
coaptation length during the PMVR procedure,
which facilitates clip positioning. Our observations
could help to improve PMVR therapy and could
make nonsurgical candidates accessible to PMVR
therapy, particularly in challenging cases with func-
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